Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs

Description:

Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Brazil with key data, information and analysis of the pricing and reimbursement steps in the country. The report closely scrutinizes the major changes in pharmaceuticals-related pricing and reimbursement in Brazil.

Due to the rapid growth in its economy, Brazil is increasingly becoming an affluent country, one which consistently spends a high proportion of its Gross domestic product (GDP) on healthcare (close to 9%, compared to the 10-12% of the US and 4-5% for other emerging nations). Through a comprehensive public health insurance programme, it aims to offer high quality healthcare provisions to the general population. While the pharmaceutical industry has grown due to the favorable regulations implemented by the government over the past two decades, the further growth of the market in Brazil will mainly arise through a direct correlation with GDP growth. This is in contrast to the growth due to an increase in the volume of the healthcare infrastructure witnessed in other emerging economies such as China and India.

The pricing of drugs in Brazil is mainly controlled by the government through various agencies such as the Agência Nacional de Vigilância Sanitária ANVISA which grants the marketing approval and the Câmara de Regulação do Mercado de Medicamentos CMED which is responsible for determining the price of new drugs and any subsequent annual price changes. While 70% of the population is covered under the public health insurance system implemented by the government, this amounts to only about 30% of the total government expenditure on drugs. About 58% of the total healthcare expenditure is accounted for by the private healthcare system. Special programs have been launched by the government to include the essential drug list, chronic diseases and diseases that require specialized treatments. Healthcare reimbursement has been well appreciated in Brazil, and many international health organizations, such as the World Health Organization (WHO) and the International Red Cross have lauded the efforts of the Brazilian government to reach out to the masses and make available quality healthcare at costs affordable to them.

Scope

- Detailed study of the healthcare scenario in Brazil.
- Analysis of the pricing and reimbursement mechanisms in Brazil.
- Details about government bodies which regulate different processes of pricing and reimbursement in Brazil.
- Details about the shares of major companies in the reimbursement program of Brazil.
- Insight into the various reimbursement programs available in Brazil.

Reasons to buy

- Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in Brazil.
- Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanism in Brazil.
- Knowledge about the regulatory bodies who undertake different processes of price registration.
- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene in Brazil.
- Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism.
1.1 List of Tables

Table 1: Pricing and Reimbursement in Brazil, Population (million), 2005-2011 11
Figure 8: Pricing and Reimbursement in Brazil, Top 10 Causes of Death in Brazil, 2008
Figure 9: Pricing and Reimbursement in Brazil, Total Healthcare Expenditure, % of GDP, 1995-2010
Figure 10: Pricing and Reimbursement in Brazil, Public Healthcare Expenditure Compared to Total Healthcare Expenditure, % of GDP, 1995-2010
Figure 11: Pricing and Reimbursement in Brazil, Private and Public Health Expenditure, % of Total Health Expenditure, 1995-2010
Figure 12: Pricing and Reimbursement in Brazil, Out-of-Pocket Healthcare Expenditure as % of Private Health Expenditure, 1995-2010
Figure 13: Pricing and Reimbursement in Brazil, Total Healthcare Expenditure as % of GDP, BRIC and The US, 2006-2010
Figure 14: Pricing and Reimbursement in Brazil, Public Healthcare Spending as % of GDP, BRIC and The US, 2010-2050
Figure 15: Pricing and Reimbursement in Brazil, Public Healthcare Spending as % of GDP, BRIC and The US, 2006-2010
Figure 16: Pricing and Reimbursement in Brazil, Per Capita Total Health Expenditure (PPP int. $), BRIC Countries, 2006-2009
Figure 17: Pricing and Reimbursement in Brazil, Per Capita Public Health Expenditure (PPP Int. $), BRIC Countries, 2006-2009
Figure 18: Pricing and Reimbursement in Brazil, Out-of-Pocket Health Expenditure as % of Private Healthcare Expenditure, BRIC and The US, 2006-2010
Figure 19: Pricing and Reimbursement in Brazil, Number of Physicians per 10,000 Population, BRIC and The US, 2010
Figure 20: Pricing and Reimbursement in Brazil, Number of Nursery and Midwifery Personnel per 10,000 Population, BRIC and The US, 2010
Figure 21: Pricing and Reimbursement in Brazil, Number of Dentistry Personnel per 10,000 Population, BRIC and The US, 2010
Figure 22: Pricing and Reimbursement in Brazil, Number of Pharmacist per 10,000 Population, BRIC and The US, 2010
Figure 23: Pricing and Reimbursement in Brazil, Number of Hospital Beds per 10,000 Population, BRIC and The US, 2009
Figure 24: Pricing and Reimbursement in Brazil, Pharmaceutical Market Forecasts ($bn), 2004-2018
Figure 25: Pricing and Reimbursement in Brazil, Pharmaceutical Market by Sub-sectors (%), 2011
Figure 26: Pricing and Reimbursement in Brazil, Pharmaceutical Market by Sub-sectors (%), 2011
Figure 27: Pricing and Reimbursement in Brazil, Pharmaceutical Market by Sub-sectors (%), 2011
Figure 28: Pricing and Reimbursement in Brazil, Market Drivers and Opportunities
Figure 29: Pricing and Reimbursement in Brazil, Market Challenges
Figure 30: Pricing and Reimbursement in Brazil, Three Kinds of Drugs According to ANVISA
Figure 31: Pricing and Reimbursement in Brazil, Regulatory Approval Process for Clinical Trials
Figure 32: Pricing and Reimbursement in Brazil, Regulatory Approval Process for Clinical Trials
Figure 33: Pricing and Reimbursement in Brazil, Healthcare Coverage Provider, By Plan Members (%), 2009
Figure 34: Pricing and Reimbursement in Brazil, Price-setting Mechanism for New Molecules
Figure 35: Pricing and Reimbursement in Brazil, The Reimbursement Process
Figure 36: Pricing and Reimbursement in Brazil, Incorporation of Technologies Prior to Formation of CITEC, 2011
Figure 37: Pricing and Reimbursement in Brazil, Incorporation of Technologies After Formation of CITEC, 2011
Figure 38: Pricing and Reimbursement in Brazil, HTA within the Brazilian Ministry of Health, 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2137586/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
- Web Address: http://www.researchandmarkets.com/reports/2137586/
- Office Code: SCD2UVDS

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof

First Name: ___________________________ Last Name: ___________________________

Email Address: * ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp